Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Merck & Co., Inc.

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Progression-Free Survival Compared to Chemotherapy Alone as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma, Regardless of Mismatch Repair Status
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Provides Update from Open-Label Arm of Phase 2 KeyVibe-002 Trial Evaluating MK-7684A, a Coformulation of Vibostolimab and Pembrolizumab, in Previously Treated Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Advanced Malignant Pleural Mesothelioma
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Present at the Barclays 2023 Global Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck’s Investigational Activin Signaling Inhibitor Sotatercept Improved Six-Minute Walk Distance by 40.8 Meters at Week 24 Versus Placebo in Adults with Pulmonary Arterial Hypertension on Background Therapy
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck’s MK-0616, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Patients with Hypercholesterolemia in Phase 2b Study
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
US FDA Approves Intramuscular Administration for Merck’s MMRV Family of Vaccines: M-M-RII (Measles, Mumps, and Rubella Virus Vaccine Live), VARIVAX (Varicella Virus Vaccine Live), and ProQuad (Measles, Mumps, Rubella and Varicella Virus Vaccine Live)
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck and AstraZeneca Provide Update on US Regulatory Review of LYNPARZA® (olaparib) for Use in Combination With Abiraterone and Prednisone or Prednisolone for the Treatment of Metastatic Castration-Resistant Prostate Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Announces Phase 3 KEYNOTE-671 Trial Met Primary Endpoint of Event-Free Survival (EFS) in Patients With Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Provides Update on Phase 3 Trials KEYNOTE-641 and KEYNOTE-789
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck and Ridgeback Provide Update on EU Marketing Authorization Application for LAGEVRIO™ (Molnupiravir)
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Opens Enrollment in New Phase 3 Clinical Trials with Investigational Once-Daily Islatravir in Combination with Doravirine for Treatment of HIV-1 Infection
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Present New Data for Sotatercept and MK-0616 at ACC.23/WCC, Demonstrating Significant Progress in Advancing Its Innovative Cardiovascular Pipeline
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Provides Update on Phase 3 MOVe-AHEAD Trial Evaluating LAGEVRIO™ (molnupiravir) for Post-exposure Prophylaxis for Prevention of COVID-19
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
U.S. FDA Accepts for Priority Review the Supplemental New Drug Application for Merck’s PREVYMIS™ for Prophylaxis of Cytomegalovirus Disease in Kidney Transplant Recipients at High Risk
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone in Patients With HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Regardless of PD-L1 Expression
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck and AstraZeneca Present Final Results of Key Secondary Overall Survival Endpoint From Phase 3 PROpel Trial at 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Announces Fourth-Quarter and Full-Year 2022 Financial Results
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
FDA Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Patients With Stage IB (T2a ≥4 Centimeters), II, or IIIA Non-Small Cell Lung Cancer (NSCLC)
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Animal Health Receives U.S. FDA Approval of Expanded Indication for BRAVECTO (fluralaner) Chews for Dogs
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Announces KEYNOTE-991 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Enzalutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer to Stop for Futility
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy in First-Line Advanced or Unresectable Biliary Tract Cancer in KEYNOTE-966 Trial
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Announces Second-Quarter 2023 Dividend
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Completes Tender Offer to Acquire Imago BioSciences, Inc.
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Named One of America’s Most JUST Companies by JUST Capital and CNBC, Industry Leader in Pharmaceuticals and Biotech
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Hold Fourth-Quarter and Full-Year 2022 Sales and Earnings Conference Call February 2
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck and Kelun-Biotech Announce Exclusive License and Collaboration Agreement for Seven Investigational Antibody-drug Conjugate Candidates for the Treatment of Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.